BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 35083713)

  • 1. Lentigo Maligna on a Difficult Location of the Face Treated with 5% Imiquimod: A Case Report of 2-Year Follow-Up.
    Misiak-Galazka M; Czuwara J; Galazka A; Czaplicka A; Rudnicka L
    Dermatol Ther (Heidelb); 2022 Feb; 12(2):599-604. PubMed ID: 35083713
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of In Vivo Reflectance Confocal Microscopy in the Analysis of Melanocytic Lesions.
    Serban ED; Farnetani F; Pellacani G; Constantin MM
    Acta Dermatovenerol Croat; 2018 Apr; 26(1):64-67. PubMed ID: 29782304
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness of 5% Topical Imiquimod for Lentigo Maligna Treatment.
    Tio DCKS; van Montfrans C; Ruijter CGH; Hoekzema R; Bekkenk MW
    Acta Derm Venereol; 2019 Sep; 99(10):884-888. PubMed ID: 31233181
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Topical Treatment of Melanoma In Situ, Lentigo Maligna, and Lentigo Maligna Melanoma with Imiquimod Cream: A Systematic Review of the Literature.
    Vaienti S; Calzari P; Nazzaro G
    Dermatol Ther (Heidelb); 2023 Oct; 13(10):2187-2215. PubMed ID: 37615838
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Topical imiquimod for periocular lentigo maligna.
    Demirci H; Shields CL; Bianciotto CG; Shields JA
    Ophthalmology; 2010 Dec; 117(12):2424-9. PubMed ID: 20591492
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of lentigo maligna with imiquimod 5% cream.
    Hopson B; Richey D; Sajben FP
    J Drugs Dermatol; 2007 Oct; 6(10):1037-40. PubMed ID: 17966182
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Topical imiquimod immunotherapy in the management of lentigo maligna.
    Powell AM; Russell-Jones R; Barlow RJ
    Clin Exp Dermatol; 2004 Jan; 29(1):15-21. PubMed ID: 14723712
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term outcomes of imiquimod-treated lentigo maligna.
    Papanikolaou M; Lawrence CM
    Clin Exp Dermatol; 2019 Aug; 44(6):631-636. PubMed ID: 30663131
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Topical Imiquimod Treatment of Lentigo Maligna.
    Ventura F; Rocha J; Fernandes JC; Pardal F; Brito C
    Case Rep Dermatol; 2009 Oct; 1(1):78-81. PubMed ID: 20652120
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of lentigo maligna with topical imiquimod.
    Naylor MF; Crowson N; Kuwahara R; Teague K; Garcia C; Mackinnis C; Haque R; Odom C; Jankey C; Cornelison RL
    Br J Dermatol; 2003 Nov; 149 Suppl 66():66-70. PubMed ID: 14616356
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A quantitative systematic review of the efficacy of imiquimod monotherapy for lentigo maligna and an analysis of factors that affect tumor clearance.
    Mora AN; Karia PS; Nguyen BM
    J Am Acad Dermatol; 2015 Aug; 73(2):205-12. PubMed ID: 26088690
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of the cellular infiltrate during successful topical treatment of lentigo maligna with imiquimod.
    Michalopoulos P; Yawalkar N; Brönnimann M; Kappeler A; Braathen LR
    Br J Dermatol; 2004 Oct; 151(4):903-6. PubMed ID: 15491436
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A systematic review on the role of imiquimod in lentigo maligna and lentigo maligna melanoma: need for standardization of treatment schedule and outcome measures.
    Tio D; van der Woude J; Prinsen CAC; Jansma EP; Hoekzema R; van Montfrans C
    J Eur Acad Dermatol Venereol; 2017 Apr; 31(4):616-624. PubMed ID: 27987308
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Lentigo maligna treated with 5% imiquimod cream].
    Martín T; Ojeda A; Martínez S; Vera A
    Actas Dermosifiliogr; 2005 Dec; 96(10):700-2. PubMed ID: 16476324
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Periocular lentigo maligna treated with imiquimod.
    O'Neill J; Ayers D; Kenealy J
    J Dermatolog Treat; 2011 Apr; 22(2):109-12. PubMed ID: 20666668
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Conservative treatment of lentigo maligna with topical imiquimod 5% cream: a case report.
    Lobo Y; Templeman R
    Dermatol Online J; 2020 Jul; 26(7):. PubMed ID: 32898412
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized trial of the off-label use of imiquimod, 5%, cream with vs without tazarotene, 0.1%, gel for the treatment of lentigo maligna, followed by conservative staged excisions.
    Hyde MA; Hadley ML; Tristani-Firouzi P; Goldgar D; Bowen GM
    Arch Dermatol; 2012 May; 148(5):592-6. PubMed ID: 22431716
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of lentigo maligna with imiquimod before staged excision.
    Cotter MA; McKenna JK; Bowen GM
    Dermatol Surg; 2008 Feb; 34(2):147-51. PubMed ID: 18093206
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Topical Imiquimod for Lentigo Maligna: Survival Analysis of 103 Cases With 17 Years Follow-up.
    Chambers M; Swetter SM; Baker C; Saunders E; Chapman MS
    J Drugs Dermatol; 2021 Mar; 20(3):346-348. PubMed ID: 33683087
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rate of Recurrence of Lentigo Maligna Treated With Off-Label Neoadjuvant Topical Imiquimod, 5%, Cream Prior to Conservatively Staged Excision.
    Donigan JM; Hyde MA; Goldgar DE; Hadley ML; Bowling M; Bowen GM
    JAMA Dermatol; 2018 Aug; 154(8):885-889. PubMed ID: 29847610
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.